Anti-psoriatic effects of indigo naturalis on the proliferation and differentiation of keratinocytes with indirubin as the active component

Journal of Dermatological Science

Volumn 54, Issue 3, 2009, Pages 168-174

  Lin, Yin Ku ^a,b   Leu, Yann Lii ^b   Yang, Sien Hung ^a,b   Chen, Hsiao Wen ^a,b   Wang, Chin Ting ^b   Pang, Jong Hwei Su ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Differentiation; Indigo naturalis; Indirubin; Keratinocyte; Proliferation; Psoriasis

Indexed keywords

CYCLINE; HERBACEOUS AGENT; INDIGO NATURALIS; INDIRUBIN; INVOLUCRIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DRUG ACTIVITY; DRUG MECHANISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KERATINOCYTE; MALE; MEDICINAL PLANT; NEWBORN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN CULTURE; WESTERN BLOTTING;

CELL CYCLE; CELL SURVIVAL; CELLS, CULTURED; DERMATOLOGIC AGENTS; DOWN-REGULATION; GENE EXPRESSION; HUMANS; INDIGOFERA; INDOLES; KERATINOCYTES; PHYTOTHERAPY; PLANT EXTRACTS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN PRECURSORS; PSORIASIS;

EID: 67349123061     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2009.02.007     Document Type: Article

References (30)

1. Yuan Z.Z., Yuan X., and Xu Z.X. Studies on tabellae indigo naturalis in treatment of psoriasis. J Tradit Chin Med 2 (1982) 306
2. Koo J., and Arain S. Traditional Chinese medicine for the treatment of dermatologic disorders. Arch Dermatol 134 (1998) 1388-1393
3. Verucchi G., Calza L., Attard L., and Chiodo F. Acute hepatitis induced by traditional Chinese herbs used in the treatment of psoriasis. J Gastroenterol Hepatol 17 (2002) 1342-1343
4. Lin Y.K., Yen H.R., Wong W.R., Yang S.H., and Pang J.H. Successful treatment of pediatric psoriasis with indigo naturalis composite ointment. Pediatr Dermatol 23 (2006) 507-510
5. Lin Y.K., Wong W.R., and Pang J.H. Successful treatment of recalcitrant psoriasis with indigo naturalis ointment. Clin Exp Dermatol 32 (2007) 99-100
6. Lin Y.K., Wong W.R., Chang Y.C., Chang C.J., Tsay P.K., Chang S.C., et al. The efficacy and safety of topically applied indigo naturalis ointment in patients with plaque-type psoriasis. Dermatology 214 (2007) 155-1561
7. Bata-Csorgo Z., Hammerberg C., Voorhees J.J., and Cooper K.D. Flow cytometric identification of proliferative subpopulations within normal human epidermis and the localization of the primary hyperproliferative population in psoriasis. J Exp Med 178 (1993) 1271-1281
8. Iizuka H., Ishida-Yamamoto A., and Honda H. Epidermal remodelling in psoriasis. Br J Dermatol 135 (1996) 433-438
9. Laporte M., and Heenen M. The heterogeneity of the germinative compartment in human epidermis and its implications in psoriasis. Dermatology 189 (1994) 340-343
10. Sano S., Chan K.S., Carbajal S., Clifford J., Peavey M., Kiguchi K., et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 11 (2005) 43-49
11. Van de Kerkhof P.C., and Vissers W.H. The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 16 (2003) 69-83
12. Bayliffe A.I., Brigandi R.A., Wilkins H.J., and Levick M.P. Emerging therapeutic targets in psoriasis. Curr Opin Pharmacol 4 (2004) 306-310
13. Gottlieb A.B. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 4 (2005) 19-34
14. Yazici A.C., Tursen U., Apa D.D., Ikizoglu G., Api H., Baz K., et al. The changes in expression of ICAM-3, Ki-67, PCNA, and CD31 in psoriatic lesions before and after methotrexate treatment. Arch Dermatol Res 297 (2005) 249-255
15. Hannuksela-Svahn A., Pääkkö P., Autio P., Reunala T., Karvonen J., and Vähäkangas K. Expression of p53 protein before and after PUVA treatment in psoriasis. Acta Derm Venereol 79 (1999) 195-199
16. Watt F.M. Involucrin and other markers of keratinocyte terminal differentiation. J Invest Dermatol 81 (1983) 100s-103s
17. Sebag M., Gulliver W., and Kremer R. Effect of 1,25 dihydroxyvitamin D3 and calcium on growth and differentiation and on c-fos and p53 gene expression in normal human keratinocytes. J Invest Dermatol 103 (1994) 323-329
18. Barker C.L., McHale M.T., Gillies A.K., Waller J., Pearce D.M., Osborne J., et al. The development and characterization of an in vitro model of psoriasis. J Invest Dermatol 123 (2004) 892-901
19. Jones P.H., and Watt F.M. Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression. Cell 73 (1993) 713-724
20. Bata-Csorgo Z., Hammerberg C., Voorhees J.J., and Cooper K.D. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest 95 (1995) 317-327
21. Ben-Arye E., Ziv M., Frenkel M., Lavi I., and Rosenman D. Complementary medicine and psoriasis: linking the patient's outlook with evidence-based medicine. Dermatology 207 (2003) 302-307
22. Tse W.P., Che C.T., Liu K., and Lin Z.X. Evaluation of the anti-proliferative properties of selected psoriasis-treating Chinese medicines on cultured HaCaT cells. J Ethnopharmacol 108 (2006) 133-141
23. Lin Y.K., Chang C.J., Chang Y.C., Wong W.R., Chang S.C., and Pang J.H. Clinical assessment of patients with recalcitrant psoriasis in a randomized, observer-blind, vehicle-controlled trial using indigo naturalis. Arch Dermatol 144 (2008) 1-8
24. Watt F.M., and Green H. Involucrin synthesis is correlated with cell size in human epidermal cultures. J Cell Biol 90 (1981) 738-742
25. Marko D., Schätzle S., Friedel A., Genzlinger A., Zankl H., Meijer L., et al. Inhibition of cyclin-dependent kinase1 (CDK1) by indirubin derivatives in human tumor cells. Br J Cancer 84 (2001) 283-289
26. Suzuki K., Adachi R., Hirayama A., Watanabe H., Otani S., Watanabe Y., et al. Indirubin, a Chinese anti-leukaemia drug, promotes neutrophilic differentiation of human myelocytic leukaemia HL-60 cells. Br J Haematol 130 (2005) 681-690
27. Hoessel R., Leclerc S., Endicott J.A., Nobel M.E., Lawrie A., Tunnah P., et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1 (1999) 60-67
28. Nam S., Buettner R., Turkson J., Kim D., Cheng J.Q., Muehlbeyer S., et al. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci USA 102 (2005) 5998-6003
29. Knockaert M., Blondel M., Bach S., Leost M., Elbi C., Hager G.L., et al. Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins. Oncogene 23 (2004) 4400-4412
30. Qiu J. 'Back to the future' for Chinese herbal medicines. Nat Rev Drug Discov 6 (2007) 506-507